(Press-News.org) Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, according to a new study led by a UCL researcher.
The finding, the researchers say, suggests there are multiple ways the drug benefits the heart, rather than its protective effect on cardiovascular health being due solely to weight loss.
The study, published in the Lancet journal and funded by Novo Nordisk, looked at data from 17,604 people aged 45 and over who were overweight and had cardiovascular disease, who were randomly assigned either weekly injections of semaglutide or placebo.
Previous analysis* of this data by the same international team found that semaglutide reduced heart attacks, strokes and other major cardiac events by 20% in this group.
In the new study, the team found that this reduction in major adverse events was similar regardless of participants’ weight at the start of the trial. That is, people only marginally classed as overweight, with a body mass index (BMI) of 27 (the average BMI for adults in the UK), saw similar benefits as those with obesity who had the highest BMIs.
The benefits were also largely independent of how much weight people lost in the first four and a half months of taking the drug. However, the researchers found a link between shrinking waistlines (the reduction in waist circumference) and heart benefits, with this accounting for a third of the drug’s protective effect on the heart after two years.
Lead author Professor John Deanfield (UCL Institute of Cardiovascular Science) said: “Abdominal fat is more dangerous for our cardiovascular health than overall weight and therefore it is not surprising to see a link between reduction in waist size and cardiovascular benefit. However, this still leaves two thirds of the heart benefits of semaglutide unexplained.
“These findings reframe what we think this medication is doing. It is labelled as a weight loss jab but its benefits for the heart are not directly related to the amount of weight lost. In fact it is a drug that directly affects heart disease and other diseases of ageing.
“This work has implications for how semaglutide is used in clinical practice. You don’t have to lose a lot of weight and you don’t need a high BMI to gain cardiovascular benefit. If your aim is to reduce cardiovascular disease, restricting its use to a limited time only and for those with the highest BMIs doesn’t make sense.
“At the same time, the benefits need to be weighed against potential side effects. Investigations of side effects become especially important given the broad range of people this medicine and others like it could help.”
While the findings focus on semaglutide, they are likely to apply to other ‘weight loss’ drugs that target the same hormone (glucagon-like peptide-1, or GLP-1).
The mechanisms by which GLP-1s may help cardiovascular health, the researchers said, include supporting the health of the lining of blood vessels, reduced inflammation, improved blood pressure control and lower lipid levels (levels of cholesterols and other fats in the bloodstream).
The study looked at data from the landmark SELECT trial – the largest and longest clinical trial of the effects of semaglutide on weight in over 17,000 adults who did not have diabetes but who were overweight or had obesity. The international team that runs the trial includes Professor Deanfield.
Semaglutide, a GLP-1 receptor agonist, simulates the functions of the body’s natural incretin hormones, which help to lower blood sugar levels after a meal. It was initially prescribed for adults with type 2 diabetes.
Semaglutide is the active ingredient in Wegovy and Ozempic. Last year, thanks to evidence from the SELECT trial, the UK medicines regulator approved Wegovy as a treatment for those with cardiovascular disease, meaning it can be prescribed privately.
On the NHS, Wegovy is prescribed for weight loss at specialist weight management clinics. Another GLP-1 agonist, Mounjaro, is prescribed by GPs in England for those with a BMI of 40 or over (or 37.5 if from a minority ethnic background) and four out of five conditions (type 2 diabetes, high blood pressure, heart and vascular disease, high cholesterol and obstructive sleep apnoea).
In their section on limitations, the authors of the new study noted that a majority of study participants were male and a high proportion were white. In future, they said, GLP-1 receptor agonist trials should examine responses by ethnicity and sex.
The preliminary analysis of SELECT data which formed the basis of this study was presented by Professor Deanfield and co-authors at the European Congress on Obesity (ECO) last year.
* https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
END
‘Weight loss’ drug helps heart regardless of amount of weight lost
2025-10-22
ELSE PRESS RELEASES FROM THIS DATE:
First truly global picture of wide inequalities in care for women’s cancers
2025-10-22
Largest-ever analysis of data on stage, treatment and consistency with international clinical guidelines, from over 275,000 women diagnosed with breast, cervical or ovarian cancer during 2015-2018 in 39 countries
For breast and cervical cancer, 40% of women in high-income countries had their cancer detected at an early stage, compared with below 20% for women in low- and middle-income countries
Ovarian cancer is least likely to be diagnosed early across the world, at less than 20%
Three-quarters (78%) of women in HICs and more than half (56%) of women in LMICs were offered surgery, but international clinical guidelines were not followed ...
International Consortium of Women’s Mental Health Experts present scientific evidence to support classification of postpartum psychosis as a distinct disease
2025-10-22
An international panel of leading experts on women’s mental health is recommending that postpartum psychosis be recognized as a distinct category of mental illness and classified accordingly within standardized medical coding systems.
The recommendation, known as a “consensus statement,” and a comprehensive review of the scientific literature on postpartum psychosis appear in the October 22 issue of Biological Psychiatry. [DOI: /10.1016/j.biopsych.2025.10.016]
Postpartum psychosis is an acute and severe psychiatric illness that sets in within weeks after delivery. ...
PET imaging of inflammation predicts recovery, guides therapy after heart attack
2025-10-22
Reston, VA (October 21, 2025)--A new approach to PET imaging offers a promising way for physicians to promptly identify patients who are at risk for poor functional recovery after a heart attack, according to new research published in The Journal of Nuclear Medicine. By visualizing CXCR4--a cellular protein that plays key role in inflammation--this technique can enable the timely implementation of treatments to mitigate inflammation and prevent heart failure progression.
Heart attack, also known as acute myocardial ...
Pennington Biomedical awarded renewal of NIH-funded Center to Advance Metabolic Disease Research and train future scientists
2025-10-22
Following a competitive review process, the National Institutes of Health (NIH) funding for Pennington Biomedical’s Metabolic Basis of Disease Center of Biomedical Research Excellence (COBRE) was renewed for an additional five years. This Phase II renewal builds on the momentum achieved since the center’s establishment in 2020, enabling continued support for young scientists who are focused on the mechanisms through which nutrition and metabolism contribute to health.
“The renewal of this center grant provides Pennington Biomedical with the opportunity to continue a metabolic ...
Planetary scientists link Jupiter’s birth to Earth’s formation zone
2025-10-22
New research from Rice University suggests that the giant planet Jupiter reshaped the early solar system in dramatic ways, carving out rings and gaps that ultimately explain one of the longest-standing puzzles in planetary science: why many primitive meteorites formed millions of years after the first solid bodies. The study, which combined hydrodynamic models of Jupiter’s growth with simulations of dust evolution and planet formation, was recently published in Science Advances.
Through state-of-the-art computer simulations, planetary scientists André Izidoro and Baibhav Srivastava found that Jupiter’s rapid ...
University of Louisville, UofL Health receive $11.5 million to develop new cancer immunotherapies
2025-10-22
Cancer remains one of the greatest health concerns in the U.S., but University of Louisville cancer researchers and UofL Health – Brown Cancer Center oncologists are improving outcomes for patients in Kentucky and beyond. UofL’s Center for Cancer Immunology and Immunotherapy (CCII), established in 2020, has been at the forefront of exciting developments in immunotherapy, using the patients’ own immune system to defeat cancer.
That work will continue and expand at UofL thanks to $11.5 million in new funding from the National Institutes of Health. The funding ...
Survey: Californians don’t know cannabis driving laws
2025-10-22
A new study from University of California San Diego has found that, while a third of Californians use cannabis regularly, there are significant gaps in knowledge around cannabis use and driving. The researchers found that even six years after the legalization of recreational cannabis use, adults in California demonstrate mixed awareness and knowledge of driving-related laws and regulations.
The study results, published in BMC Public Health, come from a large-scale survey of cannabis use in California, titled Impact 64, which was funded by the California ...
Gum disease and cavities linked to increased stroke risk
2025-10-22
EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, OCTOBER 22, 2025
Highlights:
A new study finds that having both gum disease and cavities is linked to an 86% increased risk of stroke compared to having a healthy mouth.
Poor oral health was tied to a 36% higher risk of heart attacks and other cardiovascular events.
People with regular dental visits were 81% less likely to have both gum disease and cavities.
Researchers say improving oral health could be an important — and often overlooked — way to help reduce stroke risk.
MINNEAPOLIS – People with both cavities and gum disease may face a higher risk of ischemic stroke, according to a study ...
Gum disease associated with changes in the brain
2025-10-22
EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, OCTOBER 22, 2025.
MINNEAPOLIS – Adults with gum disease may be more likely to have signs of damage to the brain’s white matter, called white matter hyperintensities, than people without gum disease, according to a new study published on October 22, 2025, in Neurology® Open Access, an official journal of the American Academy of Neurology.
White matter refers to nerve fibers that help different parts of the brain communicate. Damage to this tissue can affect memory, thinking, balance and coordination and has been linked to higher stroke risk.
White matter hyperintensities are bright spots that appear on ...
Brian Cleary awarded $2.25 million NIH grant to advance single-cell gene expression research
2025-10-22
Brian Cleary is an assistant professor in the Faculty of Computing & Data Sciences (CDS) and a core faculty member in the Bioinformatics Program. Brian also holds appointments in the Biology and Biomedical Engineering departments, and the Biological Design Center (BDC) at the Rajen Kilachand Center for Integrated Life Sciences & Engineering.
Cleary is the sole principal investigator (PI) on the five-year project, “Measuring and modeling gene expression trajectories: new computational-experimental approaches.”
The research aims to deepen understanding of how gene expression changes ...